<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108728</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0052</org_study_id>
    <nct_id>NCT04108728</nct_id>
  </id_info>
  <brief_title>Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU )</brief_title>
  <acronym>NEUROPSY-HEU</acronym>
  <official_title>Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective: to evaluate the executive functioning of the HIV exposed uninfected children&#xD;
      (HEU) versus children from the same socio-economic and cultural environment, not infected or&#xD;
      affected by HIV.&#xD;
&#xD;
      Secondary objective (s): to evaluate Intellectual Quotient, Child development, Behavior,&#xD;
      Language and investigate link between executive functioning disorders, exposure to ARVs, HIV&#xD;
      and family environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is the exploration of executive functions (EF) and screening for&#xD;
      neurodevelopment and learning disorders in children born to HIV-infected mothers, exposed to&#xD;
      the virus and to antiretrovirals (ARVs).&#xD;
&#xD;
      The evaluation of the executive functioning will be done by the score obtained at the&#xD;
      preschool BRIEF for patients and control group issued from questionnaires filled by the&#xD;
      mothers of the cases and the mothers of the controls, with matching on age, sex, level of&#xD;
      parental education and socio-economic and cultural environment.&#xD;
&#xD;
      Within the group of exposed children, factors associated with executive dysfunction including&#xD;
      HIV infection, antiretroviral exposure, maternal socio-demographic data, sociocultural and&#xD;
      environmental level will be investigated.&#xD;
&#xD;
      Evolution of the scores between J0, M12 and M24 will be compared within the group of exposed&#xD;
      children.&#xD;
&#xD;
      Compared with a control group, the child's intelligence quotient, overall development,&#xD;
      behavior and language will be compared at each follow-up time (D0, M12 and M24).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the executive function of children HEU</measure>
    <time_frame>inclusion</time_frame>
    <description>Behaviour rating inventary of executive function (BRIEF) preschool version score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intellectual quotient</measure>
    <time_frame>at INCLUSION, 12 months after inclusion, 24 months after inclusion</time_frame>
    <description>Wechsler tests score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional development</measure>
    <time_frame>at INCLUSION, 12 months after inclusion, 24 months after inclusion</time_frame>
    <description>age and stage questionnaires score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>behaviour</measure>
    <time_frame>at INCLUSION, 12 months after inclusion, 24 months after inclusion</time_frame>
    <description>Strengths and Difficulties Questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>language</measure>
    <time_frame>12 months after inclusion,</time_frame>
    <description>language dysfunction scale score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <condition>Exposure During Pregnancy</condition>
  <condition>Neurophysiologic Abnormality</condition>
  <condition>Executive Dysfunction</condition>
  <arm_group>
    <arm_group_label>HIV exposed children during pregnancy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>children born from HIV-infected mother, exposed to antiretroviral drugs during pregnancy and in the neonatal period; aged 3 years-old +/- 3 months on the date of inclusion. Parents mastering french language</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control children</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>children, aged 3 years +/- 3 months on the date of inclusion, from the same socio-economic and cultural environment, not infected or affected by HIV. Parents mastering French language.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BRIEF SCORE AT INCLUSION</intervention_name>
    <description>BRIEF SCALE evaluation</description>
    <arm_group_label>HIV exposed children during pregnancy</arm_group_label>
    <arm_group_label>control children</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  experimental:&#xD;
&#xD;
               -  HIV-positive children born to mothers living with HIV antiretrovirals during&#xD;
                  pregnancy and in the neonatal period, aged 3 years +/- 3 months on the date of&#xD;
                  inclusion.&#xD;
&#xD;
               -  Parents mastering the French.&#xD;
&#xD;
          -  control:&#xD;
&#xD;
               -  children, aged 3 years +/- 3 months on the date of inclusion, from the same&#xD;
                  socio-economic and cultural environment, no infected or affected by HIV.&#xD;
&#xD;
               -  Parents mastering French.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  great prematurity (28-32 weeks)&#xD;
&#xD;
          -  genetic anomaly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>veronique RELIQUET</last_name>
    <email>veronique.reliquet@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale FIALAIRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie LEAUTEZ-NAINVILLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VÃ©ronique RELIQUET, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

